Background Uptake of self-testing and self-management of oral anticoagulation has remained inconsistent, despite good evidence of their eff ectiveness. To clarify the value of self-monitoring of oral anticoagulation, we did a metaanalysis of individual patient data addressing several important gaps in the evidence, including an estimate of the eff ect on time to death, fi rst major haemorrhage, and thromboembolism.
Introduction
Oral anticoagulation with vitamin K antagonists substantially reduces the incidence of thromboembolic events. [1] [2] [3] [4] Although the number of patients receiving oral anticoagulants has consistently increased, uptake is limited by requirements to maintain the international normalised ratio (INR) within a narrow target range, which includes frequent testing and appropriate dose adjustments. Benefi ts shown in clinical trials might not translate into routine practice: namely the risk of major bleeding could be high in specifi c populations of patients, especially in the elderly. 2 Introduction of reliable and analytically accurate pointof-care devices allows self-testing by the patient in the home setting. 1, 2 Patients can have their test result managed by their health-care provider (self-testing) or they can interpret their INR result, and adjust their own dose of anticoagulant accordingly (self-management).
Previous systematic reviews [4] [5] [6] showed that selfmonitoring is a safe intervention, which gives rise to signifi cant reduction in thromboembolic events, while reducing the risk of death. Additionally, patients spend more time in the therapeutic range of INR than they would without self-monitoring. However, previous conclusions were limited by methodological problems and inadequate reporting of important outcome data over time. [4] [5] [6] Also important subgroup analyses, stratifi ed by age and indication for anticoagulation therapy, have not been possible.
Uptake of self-testing and self-management has remained inconsistent in and between countries, despite good evidence of their eff ectiveness and guidelines encour aging patients to discuss this option with clinical staff . 1, 7, 8 To clarify further the value of self-monitoring of oral anticoagulation we did a meta-analysis of individual patient data, which updated our previous systematic reviews and enabled more detailed analysis than previously. Specifi cally, we aimed to address several important gaps in the evidence, including obtaining an estimate of the eff ect of self-monitoring on time to death, fi rst major haemorrhage, and fi rst thromboembolic event. We also aimed to investigate eff ects in important subgroups such as the elderly and those with specifi c disease indications for anticoagulation such as atrial fi brillation or mechanical heart valve.
Methods

Search strategy and study selection
The protocol methods have been previously published. 9 We used the same search strategy as for previous reviews. [4] [5] [6] We searched Ovid versions of Embase and Medline (1966 Medline ( -2009 , limiting searches to randomised trials with a maximally sensitive strategy. 10 A list of search terms is shown in webappendix pp 1-3. We modifi ed these searches for the Cochrane Central Register of Controlled Trials, the Cochrane Library, issue 2, 2009 2, , and Cinahl (1982 2, -2009 ). We also searched for trials that are still underway or unpublished (eg, UK National Research Register and Trials Central), and handsearched reference lists of retrieved papers.
Trial eligibility and quality assessment
We included randomised trials that compared the eff ects of self-monitoring (self-testing) or self-management (self-testing and self-dosage) of anti co agulation with control and dosage by personal physician, anticoagulation management clinics, or managed services, or reported the clinical outcomes of thromboembolic events and major bleeding episodes. We included studies of adults on anticoagulant therapy irrespective of the indication for treatment, with no language restrictions.
As in our previous systematic review, 5 we assessed the quality of studies by the presence of randomisation, allocation concealment, masked outcome assessments, intention-to-treat analysis, and attrition rates. Two reviewers (CH and AW) independently assessed the articles for inclusion, and disagreements were resolved by discussion.
Data extraction
We approached all authors whose trials met the inclusion criteria and requested the following data for individual patients: date of randomisation, age, indication for treatment, type of care, demographic and psychosocial characteristics at randomisation including quality-of-life measures, treatment allocation, time to death, time to fi rst major haemorrhage, time to fi rst thromboembolic event, and INR measurements.
Data validation
We kept original data on a secure server with a back-up copy according to a prespecifi ed data-security-agree ment policy. Two researchers (CB and AF) cross-checked trial details, summary measures, and major outcomes were cross-checked with prespecifi ed outcome defi nitions against published articles. Any incon sistencies were discussed with the original trialist and corrections were made when appropriate. Requirements for authorship were those of the International Committee of Medical Journal Editors and a representative of each trial was invited to an investigators' meeting before publication to discuss analysis and results.
Statistical analysis
Primary outcomes were time to death, fi rst major haemorrhage, and fi rst thromboembolic events. Major haemorrhages included: 1) bleeding that was fatal, 2) symptomatic bleeding in a critical area or organ such as intracranial, intraspinal, intraocular, retroperitoneal, intra-articular or pericardial, or intramuscular with compartment syndrome; and 3) bleeding causing a fall in haemoglobin concentrations of 20 g/L (1·24 mmol/L) or more, or leading to transfusion of two units of packed red-blood cells. Thromboembolic events were stroke, arterial embolism, symptomatic deep-vein thrombosis, or pulmonary embolism.
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One secondary outcome was time in therapeutic range. For individual data, time-to-event outcomes were summarised as log (hazard ratio), and time in range as mean (SD). We used the survival-curve and hazard-ratio programme SCHARP (version 4) for meta-analysis of individual patient data. SCHARP is an SAS application for meta-analysis of individual patient data with a pointand-click interface that produces publication-quality graphs and appropriate summary statistics for time-toevent data. 12 We used SPSS (version 17) for analysis of baseline characteristics. We did prespecifi ed subgroup analyses for the primary outcomes with the following age bands (<55, 55-64, 65-74, and ≥75 years), the type of control-group care, type of self-monitoring, and sex. We also analysed patients who had mechanical heart valves, atrial fi brillation, and other indications separately, stratifying them by age (<65 years and ≥65 years).
Because the components of the interventions diff er somewhat (eg, in terms of their training and education) and in assuming a diff erent underlying eff ect for each trial intervention, a random eff ects model was used to calculate pooled hazard ratios. Random eff ects generally lead to wider CIs than the fi xed eff ects; however, when no heterogeneity is present the results of the fi xed and random eff ects are equivalent. Time-to-event outcomes were analysed with hazard ratios, which take into account the number and timing of events, and the time until last follow-up for each patient not experiencing an event. We used a two-step process for meta-analysis: a hazard ratio was estimated for each trial and then hazard ratios were pooled in a meta-analysis. The log-rank observed-minus-expected statistic and its variance were calculated for each trial. 13 We examined heterogeneity with the I² statistics.
14, 15 We also did tests for interaction between subgroups of patients, partitioning the total heterogeneity across all trials into within-group and between-group heterogeneity (the test for interaction). We calculated a time-specifi c number needed to treat at various timepoints with the method outlined by Altman and Andersen, 16 where at a specifi ed timepoint (t), the survival probability in the control group is Sc(t), then the survival probability in the active group is Sc (t) h , where h is the hazard ratio comparing the treatment groups. The number needed to treat represents the number of patients treated in the intervention group for one less primary outcome event over the time stipulated. For subgroups, we calculated the average eff ect over 5 years based on the control event rate. All analyses were on an intention to treat basis. We deviated from our original protocol in that we did not present data on psychological factors, which we hope to report elsewhere.
Suffi cient data from eight trials [17] [18] [19] [20] [21] [22] [23] [24] were available for us to calculate the mean time in therapeutic range at timepoints of 7 days, 30 days, 90 days, 6 months, and 1 year by the method of linear interpolation set out by Rosendaal and colleagues. 25 We assessed publication bias by constructing a funnel plot of precision (SE of the log hazard ratio) against hazard ratio for the endpoints of major haemorrhage and thromboembolic events, 6 Data are range (mean) or number (%). *Coumatrack monitor. †Coaguchek system. ‡Pro time microcoagulation system. §Two patients were unclassifi ed for indication. ¶Study stopped early. ||2236 with no mechanical heart valve, 2422 had atrial fi brillation, mechanical heart valve, or both. 
Role of the funding source
The sponsor of the study had no role in study design, data collection, data analysis, data interpretation, or writing of the report. The corresponding author had full access to all the data in the study and had fi nal responsibility for the decision to submit for publication.
Results
Of 1357 abstracts, we identifi ed 21 trials (20 published, one unpublished) that met the eligibility criteria (fi gure 1). We were unable to obtain adequate data from ten trials. [26] [27] [28] [29] [30] [31] [32] [33] [34] [35] These trials were small, ranging from 50-320 participants (total 1181 participants). Of 21 original trials, including 7598 participants, we present results for 6417 (84%) participants. Table 1 shows 11 included trials: three in the USA, 22, 24, 36 two in Germany, 18, 38 and one each from Austria and Germany, 23 Canada, 37 Denmark, 21 Nether lands, (table 1) . For all trials, we verifi ed clear methods for randomisation, allocation concealment, and intention-to-treat analyses. For publication bias, we saw no funnel-plot asymmetry and no bias with Begg's test: p=0·35 for thromboembolic events and p=1·00 for major haemorrhage; corresponding results of Egger's test were p=0·05 for thromboembolic events and p=0·92 for major haemorrhage. 3266 (51%) participants were randomly allocated to self-monitoring and 3151 to conventional care. Participants in the intervention group were on average 1·7 years (64·2 [SD 11·7] years vs 65·9 [SD 10·5] years; p<0·0001) younger than those in the control groups. A wide range of ages was included: from 17 to 94 years of age, with 99 participants aged 85 years or older. 12 800 person years of follow-up were obtained (mean 1·99 years [SD 1·22]), with a maximum follow-up of 1888 days (5·17 years).
Over a third of participants had a mechanical heart valve insertion; one trial 18 included only participants with this indication. Over half of participants had atrial fi brillation; one trial 38 included only participants with this indication. For other disorders, over 10% of participants from nine trials 17, [19] [20] [21] [22] [23] [24] 36, 37 were included. In eight trials, [17] [18] [19] [20] [21] 23, 37, 38 just under half (46%) of those in the intervention group used self-management and in three trials, 22, 24, 36 just over half (54%) used self-testing only with dose adjustments undertaken by their regular clinician (table 1) .
In four trials 18, [36] [37] [38] including a quarter of participants, primary care was used as the control and in another four trials 17, 19, 22, 24 including more than half (61%) of participants, specialist anticoagulation clinics were used (table 1) . In the three remaining trials, 20, 21, 23 the control included either primary care or specialist clinics (table 1) .
A signifi cant reduction in thromboembolic events was seen in the self-monitoring group (hazard ratio 0·51, 95% CI 0·31-0·85; p=0·010; I²=52·6%; fi gure 2). At 1 year, the number needed to treat to prevent one thromboembolic event was 78 (95% CI 55-253), and by 5 years it was 27 (19-87; table 2). Individual study hazard ratios are shown in webappendix p 4. No signifi cant reduction in major haemorrhagic events (hazard ratio 0·88, 95% CI, 0·74-1·06; p=0·18, I²=0) or in deaths (0·82, 0·62-1·09; p=0·18; I²= 37·0) were apparent with self-monitoring (fi gure 2). In prespecifi ed subgroups the rate of thromboembolic events in men was signifi cantly reduced in the selfmonitoring group (fi gure 3; p=0·010; I²=61·3) whereas in women it was not (fi gure 3; p=0·46; I²=26·6;). However, the ratio of male to female participants was four to one (5012 men vs 1405 women) and the interaction test showed that these two subgroups did not diff er signifi cantly (χ² 0·01; p=0·94). Participants younger than 55 years of age who self-monitored had a striking reduction in thromboembolic events (fi gure 3; p=0·002; I²=0), whereas in other age groups non-signifi cant eff ects were shown. In participants younger than 55 years, this result corresponded to a number needed to treat of 21 (95% CI 17-42) to prevent one thromboembolic event at 1 year. Non-signifi cant improvement in major outcomes was seen in the self-monitoring group with younger age (χ² 7·75; p=0·052).
In terms of indication, participants with a mechanical heart valve who self-monitored had signifi cant reductions in thromboembolic events (fi gure 3; p=0·001; I²=0). At 1 year the number needed to treat to prevent one event was 55 (95% CI 41-116) and by 5 years it was 24 (18-50). Eff ects for both atrial fi brillation (fi gure 3; p=0·35; I²=40·9) and other indications (fi gure 3; p=0·12; I²=0) were not signifi cant. An interaction test (χ² 6·88, p=0·032) between indications was signifi cant. Participants who self-managed oral anticoagulation also had signifi cantly fewer thromboembolic events (fi gure 4; p<0·001; I²=0), whereas participants self-testing alone did not (fi gure 4; p=0·51; I²=50·3). The interaction test between self-testing and self-management for this diff erence was signifi cant (χ² 9·81, p=0·002). For participants self-managing, the number needed to treat to prevent one thromboembolic event was 39 (95% CI 31-65). For major haemorrhage and death, we detected no signifi cant eff ects or interactions by age, sex, indication, or type of monitoring (fi gure 3). 
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Christensen 21 Cromheecke 17 Fitzmaurice 20 Koertke 18 Menéndez-Jándula 19 Siebenhofer 23 Sunderji 37 VÖller 38 Subtotal Self-testing only Kaatz 24 Matchar 22 Beyth Analysis of major outcomes in the very elderly (≥85 years, n=99) showed no signifi cant adverse eff ects of self-monitoring for all outcomes, and a reduction in mortality was seen (hazard ratio 0·44, 95% CI 0·20-0·98; p=0·044; I²=0); however, the number of participants in this analysis was small (n=75).
We postulated that type of control care in our prespecifi ed subgroups might aff ect the overall eff ectiveness of self-monitoring. Yet, little diff erence was seen in terms of anticoagulation clinic care versus primary care for thromboembolic events (fi gure 3; χ² 2·18, p=0·34); major haemorrhage (χ² 1·01, p=0·60), and death outcomes (χ² 3·25, p=0·20).
A signifi cant reduction in thromboembolic events was seen in men with a mechanical heart valve who were self-monitoring (fi gure 5; p=0·002, I²=13·8), which was not signifi cant in women (fi gure 5; p=0·99; I²=5·8). However, the number of women was small (n=447 for thrombosis) and this interaction was not signifi cant (χ² 2·04, p=0·15). Men with a mechanical valve who were self-monitoring also had a signifi cant reduction in major haemorrhagic events (fi gure 5; p=0·049; I²=0), whereas women did not (fi gure 5; p=0·69; I²=0). However, the interaction test was not signifi cant (χ² 1·31, p=0·25). Participants younger than 65 years and those 65 years or older with a mechanical heart valve who were self-monitoring oral anticoagulation showed similar signifi cant reductions with roughly a halving of thrombotic events (fi gure 5). We saw no signifi cant eff ects or interaction in terms of major haemorrhage and death for other subgroups of participants with a mechanical valve. In participants with atrial fi brillation, we saw no signifi cant eff ects across subgroups by sex or age, and no signifi cant interactions (fi gure 5).
One study 17 provided data only at 90 days for the mean time in therapeutic range (table 3). The time in therapeutic range improved and SDs decreased over time. By 1 year, four trials 18, [20] [21] [22] showed improvements in the intervention group, whereas the three trials, 19, 23, 24 which did not show improvement, all had smaller SDs in the intervention group. In the fi rst 7 days participants with atrial fi brillation and a mechanical heart valve who self-monitored oral anticoagulation spent signifi cantly more time in therapeutic range than did those who did not self-monitor 
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Data are mean (SD). (table 4, table 5 ), but over time the diff erences between groups reduced. Self-monitoring also led to an increase in the number of tests undertaken. At 1 year, participants with a mechanical valve or atrial fi brillation undertook more tests per year than did those receiving usual care (table 4, table 5 ). The substantial variation between studies was illustrated by the high heterogeneity.
Discussion
Our study used individual patient data for assessment of self-monitoring for oral anticoagulation. Overall, we observed a signifi cant reduction in thromboembolic events in the self-monitoring group. However, we did not fi nd any signifi cant eff ects for major haemorrhage or mortality.
Our fi ndings accord with those of previous systematic reviews, in which patients who self-monitor or selfmanage could improve the quality of their oralanticoagulation therapy. However, despite the decrease in the number of thromboembolic events without concomitant increases in harms, we did not see the reduction in mortality shown in previous systematic reviews. [4] [5] [6] The odds ratio in a meta-analysis by Bloomfi eld and colleagues 39 was similar to our result for reduction in thromboembolic events (odds ratio 0·58, 95% CI 0·45-0·75; p<0·001). However, the result for death was similar in eff ect size, but the observed result diff ered signifi cantly (odds ratio 0·74, 95% CI 0·63-0·87; p<0·001). This eff ect was highly hetero geneous (I²=51%), which was attributed to the largest study to date. 22 Reasons given for this high heterogeneity were that this large study had substantially longer follow-up and higher quality of control in the usual care group than did other similar studies. The trend for reduction in mortality favoured self-monitoring, yet our previous estimate for a reliable and conclusive treatment eff ect would require 5150 participants in each study group. 6 Potentially, unavailable data from the ten studies that we were unable to access, were suffi cient to remove the signifi cance of this result.
Additionally, our previous estimate that self-monitoring was feasible for only half of patients requiring anticoagulant therapy might underestimate the true numbers. In the largest trial, 22 about 80% (2922 of 3643) of trained patients were competent in the use of selfmonitoring equipment. Yet, even this estimate is confounded by eligibility criteria: in several trials 20, 32 fewer than 50% of the potentially eligible patients were randomly assigned. Self-monitoring patients deemed not com petent had higher numbers of practice attempts and higher cuvette wastage, and were less able to effi ciently do a fi ngerstick procedure. 40 Factors associated with unsuccessful self-monitoring include refusal by patients, exclusion by their family practitioner, failure to pass training, old age, poor cognition, and poor manual dexterity. 6, 20, 40 One trial excluded people unable to attend training, 19 and in another trial 20 of an unselected population, young patients were more likely to successfully self-monitor oral anticoagulatoin.
In Germany 20% (160 000) of patients on anticoagulation undertook self-management, com pared with only 1% of those in USA who did self-testing at home. Reasons for this diff erence include reim bursement, motivation by the patient, and willingness of the physician to support self-monitoring. 20 Limitations include the reluctance of individuals to participate, but also the direct costs to patients and the training required for eff ective monitoring.
In patients younger than 55 years of age, two-thirds reduction in thromboembolic events translated into 21 participants self-monitoring for 1 year to prevent one thromboembolic event. For patients with a mechanical heart valve, a 50% decrease in thromboembolic events meant that the number needed to undertake selfmonitoring to prevent one event was 55 after 1 year and 24 over 5 years. By comparison, 63 patients are needed to prevent one heart attack with daily statin therapy over 5 years. 41, 42 Patients who self-tested and adjusted their doses had signifi cantly lower rates of thromboembolic events, which suggests that patients should be given the opportunity, and provided with training, to undertake self-management. However, self-management does not mean that patients are left to fend for themselves: for instance, in one trial participants had 24 h back-up available, 37 and good quality control measures are needed. The type of control care did not aff ect the overall eff ectiveness of self-monitoring. This fi nding is often contradictory to the evidence, which shows that patients from community practices have signifi cantly worse anticoagulation control than do those from anticoagulation clinics. However, the same systematic review highlighted that patients recruited to clinical trials tended to spend more time in the therapeutic range than did those in the community. 43 For participants with atrial fi brillation we reported no signifi cant eff ects across subgroups by sex or age, and no signifi cant interactions. Participants with atrial fi bril lation were older than those with a mechanical heart valve, and in this age group, rates of events tended to be low. In a previous trial of 973 elderly patients in the community on anticoagulation, thromboembolic events were 1·4% a year. 44 Mean time in therapeutic range tended to be better in the self-monitoring groups. Importantly, even when the time in therapeutic range showed worse control, the SDs were less, which suggests lower variation and therefore more stable control of oral anticoagulation than in the control care group. 45 Full analysis of this issue is beyond the scope of this report, but is an important issue in establishing optimum anticoagulation control.
We also reported a reduction in mortality in very elderly patients who self-monitored oral anticoagulation. This result, although potentially misleading owing to the small numbers and number of analyses, warrants further investigation. The evidence already supports the use of anticoagulation for elderly patients unless contraindications apply or patients decide the benefi ts are not worth the inconvenience of such treatment. 44 Our review was restricted to adults, although increasing numbers of children receive warfarin. But self-monitoring could be a safe and eff ective management strategy for children and clinical studies are recommended. 46 Some limitations are worth noting. First, we could have missed a study, especially because of non-publication. The results diff er for publication bias because of variation in the methods for calculating Begg's and Egger's tests. Yet, the results of both suggest a weak eff ect of publication bias due to eff ects of small studies. Second, we were unable to obtain data from ten studies, although this was a small proportion of the overall dataset, which reduced the overall sample size. However, we were able to receive data from the largest trial to date, which was recently published. 22 Third, some heterogeneity in outcomes was obsereved. Diff erences occurred in the populations (ie, the monitor and the intervention populations), which all add to the inherent variability. Fourth, only a small number of participants aged over 85 years were included, and further research in this age group is needed. Finally, we do not know why fewer women than men were included and whether this is because women are reluctant to participate in self-monitoring or the overall recruitment strategies target men. One reason could be that in the largest study, 22 which comprised nearly half of the data, only 1·7% of the included participants were women. Furthermore, the study was done in a Veterans Aff airs population, which mainly includes men.
Adoption of self-monitoring will depend on fi ndings from economic analyses, which in the past have produced confl icting results. In the UK, a review concluded "in general, patient self-management is unlikely to be more cost-eff ective than the current specialised anticoagulation clinics," 47 whereas a Canadian study suggested: "selfmanagement is a cost-eff ective strategy for patients receiving long-term oral anticoagulation therapy for atrial fi brillation or for a mechanical heart valve". 48 We believe the results of our review will lead to a systematic change in practice, in terms of the signifi cant reduction in thromboembolic events in patients with a mechanical heart valve requiring long-term anticoagulation. Such patients should be off ered the option to self-manage their disease with suitable health-care support as back-up. Additionally, several reviews and our study show that self-monitoring and self-management is a safe option for suitable patients. 5, 6, 49 Contributors Members named in the writing committee contributed to the data collection or the systematic review and data analysis, and to the preparation of the published Article.
